Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lucid Diagnostics Inc. Director's Dealing 2025

May 22, 2025

33983_dirs_2025-05-22_93b207f8-68c9-4e14-8cc2-972529985368.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lucid Diagnostics Inc. (LUCD)
CIK: 0001799011
Period of Report: 2025-05-20

Reporting Person: Matheis Dennis (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-05-20 Common Stock P 187098 $1.2950 Acquired 187098 Direct
2025-05-21 Common Stock P 129684 $1.3226 Acquired 316782 Direct
2025-05-22 Common Stock P 33218 $1.3184 Acquired 350000 Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.265 to $1.30. inclusive. The reporting person undertakes to provide to Lucid Diagnostics Inc., any security holder of Lucid Diagnostics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form4.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.315 to $1.32, inclusive.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.305 to $1.32, inclusive.